首页> 外文期刊>Saudi Pharmaceutical Journal >Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs
【24h】

Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs

机译:使用外翻大鼠肠囊增强坎地沙坦西艾酯固体分散体的溶解度和肠吸收

获取原文
           

摘要

Objective: Candesartan cilexetil (CAN) is a poor aqueous soluble compound and a P-glycoprotein (P-gp) efflux pump substrate. These key factors are responsible for its incomplete intestinal absorption. Methods: In this study, we investigated to enhance the absorption of CAN by improving its solubility and inhibiting intestinal P-gp activity. A phase solubility method was used to evaluate the aqueous solubility of CAN in PVP K30 (0.2-2%). Gibbs free energy (@DG"t"r^o) values were all negative. Solubility was enhanced by the freeze drying technique. The in vitro dissolution was evaluated using the USP paddle method. The interaction between drug and carrier was evaluated by Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and Differential scanning calorimetry (DSC) studies. Naringin was selected as P-gp inhibitor. Absorption studies were performed using the everted gut sac model from rat jejunum. The drug analysis was performed by HPLC. Results: FTIR spectra revealed no interaction between drug and PVP K30. From XRD and DSC data, CAN was in the amorphous form, which explains the cumulative release of drug from its prepared systems. We noticed an enhancement of CAN absorption by improving its solubility and inhibiting the P-gp activity. The significant results (p0.05) were obtained for freeze dried solid dispersions in the presence of P-gp inhibitor than without naringin (15mg/kg) with an absorption enhancement of 8-fold. Conclusion: Naringin, a natural flavonoid, has no undesirable side effects. Therefore, it could be employed as an excipient in the form of solid dispersions to increase CAN intestinal absorption and its oral bioavailability.
机译:目的:坎地沙坦酯(CAN)是一种水溶性较差的化合物,是P-糖蛋白(P-gp)外排泵的基质。这些关键因素是肠道吸收不完全的原因。方法:在这项研究中,我们研究了通过改善CAN的溶解度和抑制肠道P-gp活性来增强CAN的吸收。使用相溶解度方法评估CAN在PVP K30中的水溶解度(0.2-2%)。吉布斯自由能(@DG“ t” r ^ o)值均为负。冷冻干燥技术提高了溶解度。使用USP桨法评估体外溶出度。通过傅立叶变换红外光谱(FTIR),X射线衍射(XRD)和差示扫描量热法(DSC)研究评估了药物与载体之间的相互作用。柚皮苷被选作P-gp抑制剂。使用大鼠空肠的外翻肠囊模型进行吸收研究。药物分析通过HPLC进行。结果:FTIR光谱显示药物与PVP K30之间没有相互作用。根据XRD和DSC数据,CAN处于无定形形式,这解释了药物从其准备系统中的累积释放。我们注意到通过提高其溶解度和抑制P-gp活性,CAN吸收得到了增强。与没有柚皮苷(15mg / kg)的情况相比,在P-gp抑制剂存在下,冷冻干燥的固体分散体获得了显着的结果(p <0.05),吸收增强了8倍。结论:天然的类黄酮柚皮苷没有不良副作用。因此,它可以以固体分散体的形式用作赋形剂,以增加CAN肠道吸收及其口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号